Exhibit 107
FORM S-8
(Form Type)
ACURX PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Table I: Newly Registered and Carry Forward Securities
| Line Item Type | Security Type |
Security Class Title | Notes | Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | ||||||||||||
| Newly Registered Securities | |||||||||||||||||||||
| Fees to be Paid | Equity | Common Stock, $0.001 par value per share | (1) | 457(c) and 457(h) | 681,227 | $ | 0.44875 | $ | 305,700.62 | 0.0001531 | $ | 46.80 | |||||||||
| Total Offering Amounts: | $ | 305,700.62 | $ | 46.80 | |||||||||||||||||
| Total Fees Previously Paid: | $ | — | |||||||||||||||||||
| Total Fee Offsets: | $ | — | |||||||||||||||||||
| Net Fee Due: | $ | 46.80 | |||||||||||||||||||
| (1) | (A) Pursuant to Rule 416 under the Securities Act of 1933 (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable under the 2021 Equity Incentive Plan (the “Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of outstanding shares of Common Stock; and (B) pursuant to Rules 457(c) and 457(h) promulgated under the Securities Act and solely for the purpose of calculating the registration fee, the maximum aggregate offering price is calculated as the product of (i) 681,227 shares of our common stock and (ii) $0.44875, the average of the high and low trading prices of common stock on The Nasdaq Capital Market on March 11, 2025 (a date within five business days prior to the date of this registration statement). |